Your shopping cart is currently empty

Vonoprazan hydrochloride, a proton pump inhibitor (PPI), effectively functions as a potassium-competitive acid blocker (P-CAB) with potent antisecretory properties. It significantly inhibits H+,K+-ATPase activity in porcine gastric microsomes, displaying an IC50 of 19 nM at pH 6.5. Developed primarily for researching acid-related conditions such as gastroesophageal reflux disease and peptic ulcer disease, vonoprazan hydrochloride also aids in the eradication of Helicobacter pylori [1] [2] [3].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 1-2 weeks | 1-2 weeks | |
| 50 mg | $1,980 | 1-2 weeks | 1-2 weeks | |
| 100 mg | $2,500 | 1-2 weeks | 1-2 weeks |
| Description | Vonoprazan hydrochloride, a proton pump inhibitor (PPI), effectively functions as a potassium-competitive acid blocker (P-CAB) with potent antisecretory properties. It significantly inhibits H+,K+-ATPase activity in porcine gastric microsomes, displaying an IC50 of 19 nM at pH 6.5. Developed primarily for researching acid-related conditions such as gastroesophageal reflux disease and peptic ulcer disease, vonoprazan hydrochloride also aids in the eradication of Helicobacter pylori [1] [2] [3]. |
| In vitro | Vonoprazan demonstrates concentration-dependent activity on porcine gastric H+, K+-ATPase, ranging from 0.1 nM to 10 μM over 30 minutes, without affecting Na+, K+-ATPase activity, even at concentrations up to 500 times its IC 50 against gastric H+, K+-ATPase [2]. |
| In vivo | Vonoprazan (1-4 mg/kg; p.o.) effectively inhibits both basal and 2-deoxy-D-glucose (200 mg/kg; s.c.)-induced gastric acid secretion in a dose-dependent manner, with complete inhibition observed at the 4 mg/kg dosage in male 7- or 8-week-old Sprague-Dawley rats [2]. This outcome suggests a proportional relationship between the administered dose of vonoprazan and its efficacy in reducing gastric acid secretion, highlighting its potential therapeutic role in conditions requiring gastric acid suppression. |
| Molecular Weight | 381.85 |
| Formula | C17H17ClFN3O2S |
| Cas No. | 1957202-44-6 |
| Smiles | Cl.CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.